End-of-day quote
Taiwan S.E.
23:00:00 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
39.3
TWD
|
+3.01%
|
|
+1.29%
|
+6.50%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
485.9
|
430.5
|
1,495
|
1,059
|
1,402
|
1,697
|
Enterprise Value (EV)
1 |
657.3
|
627.6
|
1,457
|
981.2
|
1,404
|
1,721
|
P/E ratio
|
-15.8
x
|
-13.5
x
|
-49.5
x
|
12
x
|
32.8
x
|
-16.6
x
|
Yield
|
-
|
-
|
-
|
0.73%
|
0.29%
|
-
|
Capitalization / Revenue
|
2.1
x
|
1.59
x
|
4.94
x
|
1.76
x
|
2.09
x
|
4.09
x
|
EV / Revenue
|
2.84
x
|
2.32
x
|
4.81
x
|
1.63
x
|
2.09
x
|
4.15
x
|
EV / EBITDA
|
-23.3
x
|
-21.5
x
|
-64.8
x
|
7.58
x
|
16.6
x
|
-18.7
x
|
EV / FCF
|
-12
x
|
-43.8
x
|
408
x
|
14.8
x
|
-30.9
x
|
-231
x
|
FCF Yield
|
-8.33%
|
-2.28%
|
0.25%
|
6.76%
|
-3.24%
|
-0.43%
|
Price to Book
|
2.03
x
|
2.08
x
|
3.32
x
|
1.95
x
|
2.41
x
|
3.13
x
|
Nbr of stocks (in thousands)
|
32,014
|
32,014
|
46,000
|
46,000
|
46,000
|
46,000
|
Reference price
2 |
15.18
|
13.45
|
32.50
|
23.01
|
30.49
|
36.90
|
Announcement Date
|
15/04/19
|
20/03/20
|
24/03/21
|
29/04/22
|
11/04/23
|
14/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
231.8
|
270.6
|
302.9
|
600.7
|
670.6
|
415
|
EBITDA
1 |
-28.21
|
-29.19
|
-22.5
|
129.4
|
84.62
|
-91.96
|
EBIT
1 |
-38.04
|
-40.36
|
-34.58
|
112.9
|
56.26
|
-125.8
|
Operating Margin
|
-16.41%
|
-14.92%
|
-11.42%
|
18.79%
|
8.39%
|
-30.32%
|
Earnings before Tax (EBT)
1 |
-38.34
|
-39.93
|
-32.48
|
115.3
|
56.36
|
-124.8
|
Net income
1 |
-30.72
|
-31.87
|
-26.15
|
89.44
|
43.06
|
-102.5
|
Net margin
|
-13.25%
|
-11.78%
|
-8.63%
|
14.89%
|
6.42%
|
-24.69%
|
EPS
2 |
-0.9613
|
-0.9974
|
-0.6563
|
1.914
|
0.9287
|
-2.223
|
Free Cash Flow
1 |
-54.73
|
-14.33
|
3.573
|
66.29
|
-45.42
|
-7.448
|
FCF margin
|
-23.61%
|
-5.3%
|
1.18%
|
11.04%
|
-6.77%
|
-1.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
51.21%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
74.12%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.1685
|
0.0876
|
-
|
Announcement Date
|
15/04/19
|
20/03/20
|
24/03/21
|
29/04/22
|
11/04/23
|
14/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
171
|
197
|
-
|
-
|
1.67
|
24
|
Net Cash position
1 |
-
|
-
|
37.7
|
77.5
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-6.075
x
|
-6.751
x
|
-
|
-
|
0.0197
x
|
-0.2612
x
|
Free Cash Flow
1 |
-54.7
|
-14.3
|
3.57
|
66.3
|
-45.4
|
-7.45
|
ROE (net income / shareholders' equity)
|
-12%
|
-14.3%
|
-7.95%
|
18.1%
|
7.55%
|
-17.7%
|
ROA (Net income/ Total Assets)
|
-4.85%
|
-4.94%
|
-3.94%
|
10.6%
|
4.42%
|
-8.66%
|
Assets
1 |
632.8
|
644.8
|
664.3
|
847.6
|
973.4
|
1,184
|
Book Value Per Share
2 |
7.460
|
6.470
|
9.800
|
11.80
|
12.70
|
11.80
|
Cash Flow per Share
2 |
1.550
|
0.8300
|
1.880
|
3.930
|
2.730
|
3.810
|
Capex
1 |
56.4
|
1.91
|
0.46
|
8.71
|
110
|
28.8
|
Capex / Sales
|
24.35%
|
0.7%
|
0.15%
|
1.45%
|
16.45%
|
6.95%
|
Announcement Date
|
15/04/19
|
20/03/20
|
24/03/21
|
29/04/22
|
11/04/23
|
14/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +6.50% | 61.29M | | -11.06% | 1.15B | | -20.55% | 130M | | -0.78% | 72.61M | | +1.12% | 55.32M | | -2.99% | 50.98M |
Bio Medical Devices
|